Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Aquestive Therapeutics Q4 2025 Earnings Call - Targets Q3 2026 NDA Resubmission for Anaphylm After FDA Type A Request
Aquestive presented a confident, operationally focused update: management has requested a Type A meeting with the FDA (expected within ~30 days), selected CROs and drafted protocols for the two studie...
- Aquestive has submitted a Type A meeting request to the FDA and expects the meeting within ~30 days, following the CRL focused on human factors and a PK study.
- Management is guiding a resubmission of the Anaphylm NDA in Q3 2026, saying they have a "clear and achievable" path to satisfy FDA requests.
- The company has selected CROs and drafted protocols for the two FDA-requested studies, the human factors validation study and a PK study, and is already preparing for dosing.
- +13 more takeaways
CorMedix Q4 2025 Earnings Call - DefenCath guidance affirmed as TDAPA shifts to bundled add-on, REZZAYO Phase 3 readout set for Q2 2026
CorMedix closed a transformational 2025: the Melinta acquisition closed in August, management achieved the targeted $35 million of synergies in Q4, and full-year pro forma revenue reached $401.3 milli...
- CorMedix closed Melinta acquisition in August 2025 and achieved targeted synergies of $35 million during Q4 2025.
- Pro forma full-year 2025 revenue was $401.3 million, in line with prior guidance.
- Q4 2025 net revenue was $128.6 million, with DefenCath contributing $91.2 million and the Melinta portfolio $37.4 million.
- +17 more takeaways
Myers Industries Q4 2025 Earnings Call - Transformation and MTS Divestiture Drive Margin Expansion and FCF Recovery
Myers pitched 2025 as an inflection year. Management executed a focused transformation, exited low‑margin lines and idled two of nine rotational molding facilities, and announced the strategic decisio...
- Q4 net sales were $204.0 million, essentially flat year over year; full year 2025 net sales were $825.7 million, down 1.3% versus 2024.
- Management completed a strategic review and announced the decision to sell Myers Tire Supply, with MTS expected to be treated as discontinued operations beginning in Q1 2026, which will alter future comparability and outlooks for automotive aftermarket exposure.
- Adjusted gross margin in Q4 expanded 140 basis points to 33.6%, and adjusted operating margin widened 230 basis points to 11.0%, reflecting favorable mix, higher volume, and focused transformation savings.
- +11 more takeaways
flyExclusive Q4 2025 Earnings Call - First Positive Adjusted EBITDA as Fleet Reset Drives Structural Profitability
flyExclusive says 2025 was a turning point. The company removed non-performing aircraft, modernized the fleet, and tightened execution, producing a 15% revenue gain to $375.9 million, a 53% jump in gr...
- Q4 2025 Adjusted EBITDA turned positive at $6.6 million, representing a 6% Adjusted EBITDA margin, the first positive quarter since going public.
- Full year 2025 revenue was $375.9 million, up 15% year-over-year, with Q4 revenue of $104.3 million, up 14% year-over-year.
- Fly hours increased roughly 12% for the year to about 75,000, and Q4 flight hours rose about 13% to ~20,400 hours, even with a fleet 14% smaller versus 2024.
- +14 more takeaways
Lightwave Logic Q4 and Full Year 2025 Earnings Call - Foundry integrations deepen; 2027 earliest production ramp
Lightwave Logic spent 2025 moving from lab validation toward foundry-ready commercialization. The company reports material progress on its Perkinamine electro-optic polymer platform, deeper reliabilit...
- Perkinamine polymer platform showed meaningful execution progress in 2025, with improved reliability data addressing temperature stability and photo-oxidation concerns from prior generations.
- Three customer programs reached stage 3 (prototype to final product) in 2025, and Lightwave Logic added a fourth Fortune Global 500 customer in early 2026; roughly 15 additional engagements are in stage 1 or 2.
- Company expects 2026 revenue to be driven primarily by material supply and non‑recurring engineering work; volume production and licensing revenues are not anticipated until 2027 at the earliest.
- +11 more takeaways
Palladyne AI Q4 2025 Earnings Call - Reiterated $24M-$27M 2026 Guidance as Vertical Integration Starts to Drive Backlog
Palladyne AI told investors it has moved from a development-stage AI shop to a vertically integrated industrial and defense platform after three November acquisitions, and is reiterating 2026 revenue ...
- Reiterated 2026 revenue guidance of $24 million to $27 million, roughly 4x–5x 2025 revenue, and management expects organic growth plus M&A contribution across AI, UAV, and manufacturing segments.
- Backlog rose from about $13.5 million at 12/31/2025 to nearly $18 million midway through Q1 2026, reflecting new contract wins net of invoicing activity.
- Q4 2025 revenue was $1.7 million, up 118% year-over-year, but that included approximately six weeks of contribution from the November acquisitions.
- +12 more takeaways
Kura Oncology Q4 and FY 2025 Earnings Call - Komzifti launch shows early commercial traction, payer step edits, and push into frontline AML
Kura closed 2025 with Komzifti on the market and clear early momentum. The product generated $2.1 million in net product revenue in the final weeks of the year, triggered a $135 million collaboration ...
- Komzifti launched in late 2025 and generated $2.1 million in net product revenue in the final weeks of the quarter.
- The first commercial sale triggered a $135 million milestone payment under the Kyowa Kirin collaboration; Q4 receipts tied to the launch and KOMET-017 milestones were ~$195 million.
- Komzifti was listed in the FDA Orange Book with patent protection through July 2044, extending the franchise runway.
- +12 more takeaways
Tuniu Corporation Q4 2025 Earnings Call - Returned to profitability and announced up to $50M shareholder return plan
Tuniu closed 2025 with momentum and a clear message to shareholders. Q4 net revenues rose 20% year-over-year to RMB 123.5 million, led by package tours which jumped 35% to RMB 102.1 million and made u...
- Tuniu reported Q4 2025 net revenues of RMB 123.5 million, up 20% year-over-year.
- Package tour revenue drove the quarter, rising 35% to RMB 102.1 million and representing 83% of Q4 net revenues.
- Full year 2025 net revenues were RMB 578 million, a 13% increase year-over-year, with package tours at RMB 493.5 million, up 21%.
- +15 more takeaways
Bilibili Q4 2025 Earnings Call - Profitability Arrives as AI and Community Power an Ad Surge
Bilibili closed 2025 with a clear inflection, delivering its first full year of GAAP profitability while user engagement, creator monetization, and advertising all accelerated into year-end. Managemen...
- Bilibili reported Q4 2025 revenue of RMB 8.3 billion, up 8% year-over-year; full-year revenue reached RMB 30.3 billion, up 13% YoY.
- The company achieved its first full year of GAAP profitability, reporting a FY2025 GAAP net profit of RMB 1.2 billion.
- Q4 gross profit rose 11% YoY and gross margin expanded to 37.0%, the 14th consecutive quarter of margin expansion.
- +16 more takeaways
Autohome Q4 2025 Earnings Call - Transforming into an AI-powered O2O Auto Transaction Ecosystem
Autohome used the Q4 release to paint a clear strategic pivot. The company is shifting from a pure automotive media and lead-generation platform to a one-stop online-to-offline transaction and service...
- Strategic pivot announced, Autohome aims to evolve from an automotive information platform into a one-stop O2O transaction and services ecosystem, with AI as the engine for product innovation and operations.
- Q4 2025 net revenue was CNY 1.46 billion, split into media services CNY 334 million, lead generation CNY 668 million, and online marketplace and others CNY 460 million.
- Full-year 2025 revenue reached CNY 6.45 billion, with media services CNY 1.15 billion, lead generation CNY 2.71 billion, and online marketplace and others CNY 2.59 billion, the latter up 8.8% year-over-year.
- +11 more takeaways